CSRxP Statement on Trump Administration’s Latest Drug Pricing Proposal

Feb 1, 2019

For Immediate Release: 
Contact: Lauren Blair
(201) 213-5004
[email protected]

The Campaign for Sustainable Rx Pricing (CSRxP) executive director, Lauren Aronson, issued the following statement in response to the Trump Administration’s latest proposed drug pricing rule:

“We appreciate this administration’s continued work to tackle out-of-control drug prices.  It’s clear President Trump and U.S. Health and Human Services Secretary Azar are committed to making prescription drugs more affordable.

“As we have said before, protecting the ability of pharmacy benefit managers to negotiate lower prices on behalf of patients is a critical aspect in that effort, keeping costs low, and protecting the choice and access Medicare Part D beneficiaries enjoy today.

“While we applaud the rule’s intent, it misses the central problem with prescription drug prices: big pharma’s price setting.  We need to focus on real solutions that lower costs, not raise them even further.  As millions of Americans struggle to afford their medication, the industry is prospering.  In blocking competition and protecting their monopolies, drug makers continue to increase prices exorbitantly and enrich their bottom lines, putting profit margins ahead of patient needs despite immense public scrutiny.  This trend must end.  CSRxP remains steadfast in our commitment to hold Big Pharma accountable for price gouging and put patients first.”